Humacyte, Inc: Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Humacyte (Nasdaq: HUMA) reported Q2 2026 results and updated its pipeline. In its V012 Phase 3 dialysis access trial, ATEV outperformed AV fistula in an interim analysis of 80 female patients, with fewer catheter days and infections. Humacyte plans an sBLA filing in 2H 2026. FDA accepted an IND for CTEV in CABG; Phase 2a expected to start Q3 2026. Symvess sales were $0.4M in Q2 2026 vs $0.1M in Q2 2025.
How this was made
The 30-second read
Why it matters
The article’s newest decision-relevant facts are the V012 Phase 3 interim results supporting a 2H 2026 sBLA filing and FDA IND acceptance for CTEV with a Phase 2a start planned for Q3 2026, plus Q2 Symvess sales and management’s commercial reset.
Market read
Traders can frame HUMA around upcoming regulatory submissions and trial initiation windows, while monitoring whether commercial execution improves beyond low current sales.
What to watch
Symvess sales are still small ($0.4M vs $0.1M), so near-term fundamentals may remain weak even if clinical/regulatory milestones progress.
Background
Humacyte is a commercial-stage biotech developing bioengineered human tissues, with Symvess as a commercial product and V012/CTEV as pipeline programs.
Ticker impact
Humacyte reports Q2 results and says V012 Phase 3 interim data outperformed AV fistula, supporting a supplemental BLA filing in 2H 2026.
Near-term upside bias possible on biotech sentiment, with follow-through dependent on FDA review timelines and subsequent trial updates.
The article discloses specific interim efficacy/safety metrics for V012, a planned sBLA submission window, and FDA IND acceptance for CTEV, all of which are concrete, time-linked catalysts for HUMA.
Market effects
Reinforces the dialysis access and tissue-engineered vascular conduit theme, potentially supporting sentiment for adjacent regenerative medicine and vascular device developers.
Limited direct regional impact; primarily US FDA and US dialysis commercialization narrative.
International commercialization signals (Israel review acceptance mentioned) may modestly broaden perceived market opportunity beyond the US.
Counterpoint
Interim Phase 3 data in the first 80 patients and a planned sBLA filing window may not translate into approval timing, leaving substantial regulatory and execution risk.
Key entities
- companyHumacyte, Inc.
Nasdaq-listed company advancing tissue-engineered vascular conduits and reporting Q2 2026 results and pipeline/regulatory updates.
- clinical_programV012 (ATEV)
Phase 3 dialysis access program; interim analysis in women shows ATEV outperformed AV fistula on catheter-free days and infection rates.
- clinical_programCTEV
Coronary tissue engineered vessel; FDA accepted IND for first-in-human CABG study, with Phase 2a planned to start Q3 2026.
- regulatorFDA
Accepted IND for CTEV and is the agency for the planned sBLA filing for dialysis access.
- productSymvess
Commercial product; Q2 2026 sales reported at $0.4M versus $0.1M in 2025.
